Gabrail Cancer Center

What Gabrail Cancer Center does

Gabrail Cancer Center (GCC) is a privately held, vertically integrated community oncology and hematology practice founded in 1990 by Dr. Nashat Gabrail and headquartered at 4875 Higbee Ave NW in Canton, Ohio, with a satellite office in Tuscarawas County. The center delivers comprehensive cancer care — including chemotherapy and infusion therapy, on-site CLIA-certified laboratory services, ACR-accredited CT imaging, and the in-house Liberty Pharmacy — and operates a Family Cancer Registry for hereditary risk assessment. Beyond clinical care, GCC runs a dedicated 16-room Phase 1 Clinical Trials Unit with overnight monitoring capability and reports more than 200 Phase I studies and more than 500 Phase II–IV oncology studies conducted, with 25 trials actively recruiting on average and a stated 90% first-to-open-and-enroll track record.

The business operates across two distinct revenue engines. The first is patient treatment services, billed through insurance with in-house financial counseling and pharmaceutical assistance support. The second is clinical research services, conducted on behalf of pharmaceutical companies, biotech firms, CROs, and government agencies, including first-in-human, single and multiple ascending dose, adaptive, food-effect, drug-drug interaction, and bioequivalence studies. Patients are acquired via physician referrals, self-referrals, and active clinical trial recruitment, with the practice drawing patients nationally and internationally.

GCC has 11–50 employees organized around a Medical Director/CEO (Dr. Gabrail), a COO (Carrie Smith) overseeing the clinical trial pipeline, a regulatory manager, clinical data management, study coordinators, infusion and lab staff, and Liberty Pharmacy personnel. The practice has recently expanded its clinical research footprint by joining PhaseWell Research, a clinical research site company, and adding new sponsor partnerships including Genprex's Acclaim-1 and Acclaim-3 lung cancer gene therapy trials in November 2025. No external institutional ownership, PE involvement, or public listing is evidenced.

Name

Gabrail Cancer Center

Legal name

Gabrail Cancer Center

Website

https://gabrailcancercenter.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

11–50 employees

Short description

Gabrail Cancer Center is a privately held, vertically integrated community oncology and hematology practice in Canton, Ohio, founded in 1990, serving cancer patients locally and nationally with infusion therapy, on-site lab and imaging, an in-house pharmacy, and a dedicated Phase 1 clinical trials unit.

Ownership category

akta.pro rank

Product category

Oncology and Hematology Care Services

NAICS

Offices of Physicians (62111), Medical and Diagnostic Laboratories (6215), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

Keywords

• Oncology treatment services
• Clinical research trials
• Infusion therapy
• Hematology care
• Cancer care

Headquarters

HQ city

Canton

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Patient Treatment Services: Revenue generated from providing oncology and hematology treatment services to patients, including chemotherapy, infusion therapy, and related medical care. Services are billed through insurance with financial counselors assisting patients with insurance claims and pharmaceutical assistance programs.
2. Clinical Research Trials: Revenue generated from conducting clinical trials on behalf of pharmaceutical companies, biotech firms, and government agencies. GCC has conducted more than 200 Phase I studies and more than 500 Phase II-IV oncology studies. Services include rapid startup (90% of the time first site to open and enroll), high patient retention, and accurate data collection.
3. In-House Pharmacy (Liberty Pharmacy): The Liberty Pharmacy, located within Gabrail Cancer Center, serves as a retail pharmacy providing patients access to affordable medications. Accepts most insurances, offers financial assistance and discounted cash payment rates. Operates Monday-Thursday 8:00AM-4:00PM and Friday 8:00AM-2:00PM.
4. Instant Imaging Services: On-site medical imaging services including CT scans, provided at low cost. The center is ACR Accredited and provides timely scan results, generating revenue from imaging services billed to insurance.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Gabrail Cancer Center is a privately held medical oncology and hematology practice providing cancer treatment, infusion therapy, on-site laboratory services, ACR-accredited CT imaging, an in-house Liberty Pharmacy, and a Family Cancer Registry, alongside Phase I-IV clinical trial operations for pharmaceutical and biotech sponsors. The center treats over 200 cancer subtypes and has conducted more than 200 Phase I and 500+ Phase II-IV oncology studies. A 16-room dedicated Phase 1 Clinical Trials Unit supports overnight patient stays and specialized pharmacokinetic studies.

Product overview

Gabrail Cancer Center is a comprehensive oncology and clinical research center offering a unified suite of healthcare services. The center provides clinical research services conducting Phase I through Phase IV oncology trials, infusion therapy, on-site laboratory services, ACR-accredited instant imaging (CT scans), an in-house Liberty Pharmacy, and a Family Cancer Registry for early cancer detection. The Phase 1 Clinical Trials Unit, featuring 16 private rooms with overnight observation capability, complements the broader clinical research program. Together, these services enable patients to receive cutting-edge treatments and clinical trial participation without traveling long distances, while the center's research operations support pharmaceutical and biotech drug development.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Services Phase I, II, III, and IV oncology clinical trial management services for pharmaceutical companies, biotech firms, CROs, and government agencies, supported by a dedicated research team and specialized PK/pharmacodynamics study capabilities.
• Infusion Therapy Chemotherapy and therapeutic infusion services for cancer as well as other conditions including osteoporosis, Crohn's disease, gout, asthma, and multiple sclerosis, delivered in a 20-chair infusion suite.
• On-Site Laboratory Services CLIA-certified on-site laboratory providing routine blood work and most lab results within 24 hours, supporting cancer treatment monitoring and trial specimen handling.
• Instant Imaging ACR-accredited on-site medical imaging including CT scans with elective reports within 24-48 hours and same-minute turnaround for emergency cases, with low-cost cash pricing.
• The Liberty Pharmacy In-house retail pharmacy providing cancer and supportive-care medications to patients; accepts most insurances, offers financial assistance, drive-thru service, and discounted cash payment rates.
• Family Cancer Registry Pedigree-based early cancer detection program that evaluates families for cancer susceptibility and provides individualized risk assessment, prevention counseling, and early detection services.
• Phase 1 Clinical Trials Unit Dedicated 16-room Phase 1 unit with private bedrooms, 20 infusion chairs, 24-hour patient monitoring, kitchen, common area, and on-site pharmacy and laboratory support for week-long patient stays.
• Clinical Trial Matching Open clinical trials listing and matching service across multiple cancer types including breast, colon, lung, melanoma, leukemia, multiple myeloma, and solid tumors, supporting patient recruitment into actively enrolling studies.

Quantifiable outcome

• Over 200 different cancer subtypes treated annually by Dr. Gabrail
• +6 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

14 partnerships are on record, tiered minor and core.

• Genprex, Inc.minorStrategic or Co-development Partner · 19 November 2025Genprex, Inc. added Gabrail Cancer Center in Ohio as a new clinical trial site for its lung cancer gene therapy studies, Acclaim-1 and Acclaim-3. The partnership expands Genprex's clinical trial site network to accelerate enrollment and advance research into lung cancer gene therapy treatments.
• PhaseWell ResearchcoreStrategic or Co-development PartnerGabrail Cancer Center Research joined PhaseWell Research, a clinical research site company united by a shared commitment to advance the future of medicine. PhaseWell is described as a clinical research site company.
• SargoncoreTechnology or IntegrationSargon is listed as an affiliate of Gabrail Cancer Center. Contact: Carrie Smith at [email protected]. Sargon appears to be a research-related affiliate company.
• CRT (Clinical Research Trial affiliate)coreTechnology or IntegrationCRT is listed as an affiliate of Gabrail Cancer Center. Contact: (330) 492-3345. CRT appears to be a clinical research affiliate organization.
• Liberty PharmacycoreTechnology or IntegrationThe Liberty Pharmacy is an in-house affiliated pharmacy located within Gabrail Cancer Center. It provides affordable medications to patients, accepts most insurances, offers financial assistance and discounted rates for cash payments. Contact: Andrew Stine, (330) 490-9034.
• Central IRBcoreStrategic or Co-development PartnerGabrail Cancer Center utilizes Central IRB for oversight of clinical trials, providing regulatory review and approval services for research studies.
• Gabrail Cancer Center IBC (Institutional Biosafety Committee)coreStrategic or Co-development PartnerInternal Institutional Biosafety Committee providing oversight for biosafety aspects of clinical research, particularly important for gene therapy and novel biological agent trials.
• Pharmaceutical Companies and CROscoreStrategic or Co-development PartnerGCC partners with pharmaceutical companies and contract research organizations (CROs) to perform Investigator Initiated Research, Bioequivalence studies, Special PK studies, Phase I, Phase II, and Phase III studies. GCC has a strong history of such partnerships.
• Government AgenciescoreStrategic or Co-development PartnerGCC partners with government agencies for clinical research studies, in addition to pharmaceutical companies and CROs.
• Acurian HealthminorGTM or Marketing PartnerAcurian Health is listed as a resource partner on GCC's website. Acurian Health notifies patients of clinical trials in their local area.
• National Cancer Institute (NCI)minorGTM or Marketing PartnerListed as a resource partner providing a database of cancer-specific clinical trials. NCI is a primary U.S. government agency for cancer research and clinical trial information.
• ClinicalTrials.govminorGTM or Marketing PartnerListed as a resource partner. ClinicalTrials.gov is a database of clinical trials run by the US National Library of Medicine, offering free help finding trials at 1-800-4-CANCER.
• TrialCheckminorGTM or Marketing PartnerListed as a resource partner. TrialCheck lists clinical trials and includes a hospital directory for patient matching.
• CenterWatchminorGTM or Marketing PartnerListed as a resource partner. CenterWatch provides proprietary data and information analysis on clinical trials through databases, market research, and information services.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Florida Cancer Specialists & Research Institute: Large community oncology practice with an integrated Phase 1 clinical trials program and infusion, imaging, lab, and pharmacy services. Highly comparable to Gabrail's vertically integrated, research-led community model, but at materially greater scale.
• Texas Oncology: One of the largest U.S. community oncology networks with significant in-house clinical research across Phase I–IV oncology trials, plus on-site imaging, lab, and pharmacy. Directly comparable in service mix and trial leadership model, though far broader geographically.
• Highlands Oncology Group: Community-based oncology practice with a dedicated Phase 1 clinical trials unit, infusion, imaging, and on-site lab. Most directly comparable to Gabrail in scale and integrated service offering, anchored in a similar founder-led, research-strong model.
• Sarah Cannon Research Institute: Community-based oncology clinical research organization running Phase I trials across a network of sites, with the same core value proposition Gabrail offers sponsors: rapid enrollment, first-in-human capability, and community-site speed.
• The Oncology Institute of Hope and Innovation (TOI): Public community oncology practice operator with infusion, lab, imaging, and clinical trials. Closely mirrors GCC's vertically integrated community oncology business model and value-based care orientation, though at a multi-state scale.

Broad incumbents

• US Oncology Research (McKesson): Large, established community oncology research network within McKesson. Overlaps with GCC's sponsor-facing clinical trials offering and community oncology footprint, and is the most relevant incumbent that GCC competes with for trial allocations.
• IQVIA (Oncology / Site Solutions): Global CRO and clinical trial site network operator that interfaces with community oncology sites like Gabrail for Phase I–IV oncology studies. Relevant as both a potential channel partner and as a competitive force in the trial-site market GCC serves.
• OneOncology: Network/platform for community oncology practices providing shared services, payer contracting, and clinical research infrastructure. Comparable to GCC as a community oncology platform and a likely competitor or acquirer in GCC's strategic landscape.

Regional players

• Virginia Cancer Specialists: Multi-site community oncology practice with an active clinical research program across Phase I–III trials. Comparable in service mix and trial portfolio to GCC, though operating in the Mid-Atlantic rather than the Midwest.
• Willamette Valley Cancer Institute and Research Center: Community oncology practice with a strong research arm including Phase I trials, infusion, imaging, and lab services. Comparable operating model to GCC, though focused on the Pacific Northwest.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/GabrailCancerCenter
• LinkedInlinkedin.com/company/gabrail-cancer-ctr
• Instagraminstagram.com/gabrailcancerresearchcenter
• Xx.com/gabrailcc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gabrail Cancer Center